Related Experiment Video

Updated: May 29, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q Baggstrom1, Yingwei Qi, Marianna Koczywas

  • 1Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA. Mbaggstr@dom.wustl.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|September 16, 2011
PubMed
Abstract

Insights

The study found that AT-101, an inhibitor of antiapoptotic Bcl proteins, showed no efficacy in patients with recurrent small cell lung cancer (SCLC). Further research into AT-101 for SCLC treatment is not recommended.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • AT-101 targets antiapoptotic Bcl proteins and induces pro-apoptotic proteins.
  • Small cell lung cancer (SCLC) is an aggressive form of lung cancer.

Purpose of the Study:

  • To evaluate the efficacy of AT-101 in patients with recurrent, chemosensitive, extensive-stage SCLC.

Main Methods:

  • Eligible patients had recurrent sensitive SCLC.
  • AT-101 was administered orally at 20 mg daily for 21 of 28 days per cycle.
  • The primary endpoint was the objective response rate.

Main Results:

  • The study was terminated early due to lack of response in 14 evaluable patients.
  • No objective responses were observed.
  • Three patients (21%) achieved stable disease.
  • Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting.

Conclusions:

  • AT-101 demonstrated no activity in patients with recurrent chemosensitive SCLC.
  • The drug is not effective for this patient population.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...